- Home
- PKG vs RPRX Comparison
PKG vs RPRX Comparison
Compare PKG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKG
- RPRX
- Stock Information
- Founded
- PKG 1867
- RPRX 1996
- Country
- PKG United States
- RPRX United States
- Employees
- PKG N/A
- RPRX N/A
- Industry
- PKG Containers/Packaging
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- PKG Consumer Discretionary
- RPRX Health Care
- Exchange
- PKG Nasdaq
- RPRX Nasdaq
- Market Cap
- PKG 18.5B
- RPRX 16.2B
- IPO Year
- PKG 2000
- RPRX 2020
- Fundamental
- Price
- PKG $197.90
- RPRX $39.23
- Analyst Decision
- PKG Buy
- RPRX Strong Buy
- Analyst Count
- PKG 7
- RPRX 3
- Target Price
- PKG $233.00
- RPRX $46.00
- AVG Volume (30 Days)
- PKG 885.1K
- RPRX 3.8M
- Earning Date
- PKG 10-22-2025
- RPRX 11-05-2025
- Dividend Yield
- PKG 2.52%
- RPRX 2.21%
- EPS Growth
- PKG 15.38
- RPRX N/A
- EPS
- PKG 9.90
- RPRX 1.75
- Revenue
- PKG $8,771,800,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- PKG $9.53
- RPRX $36.16
- Revenue Next Year
- PKG $13.55
- RPRX $2.04
- P/E Ratio
- PKG $20.01
- RPRX $22.68
- Revenue Growth
- PKG 7.30
- RPRX 3.70
- 52 Week Low
- PKG $172.72
- RPRX $24.05
- 52 Week High
- PKG $250.82
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- PKG 40.27
- RPRX 59.26
- Support Level
- PKG $195.75
- RPRX $38.39
- Resistance Level
- PKG $204.11
- RPRX $40.01
- Average True Range (ATR)
- PKG 3.99
- RPRX 1.26
- MACD
- PKG 0.23
- RPRX 0.12
- Stochastic Oscillator
- PKG 31.03
- RPRX 63.19
About PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.